Page last updated: 2024-12-05

benzimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzimidazole is a heterocyclic aromatic organic compound with the formula C7H6N2. It is a white solid that is soluble in most organic solvents. Benzimidazole is an important building block in many pharmaceuticals, including antifungal agents, antiparasitic drugs, and anti-cancer agents. Benzimidazole derivatives are also used as dyes, pigments, and antioxidants. The structure of benzimidazole can be viewed as a benzene ring fused with an imidazole ring. The imidazole ring in benzimidazole is weakly basic and readily undergoes reactions with electrophiles. The most common synthetic route to benzimidazole derivatives involves the condensation of o-phenylenediamine with a carboxylic acid or a carboxylic acid derivative. Benzimidazoles have been studied for their medicinal properties for many years. For example, mebendazole and albendazole are benzimidazole derivatives that are used to treat parasitic infections. The anti-cancer drug tirapazamine is also a benzimidazole derivative. The importance of benzimidazoles in medicinal chemistry lies in their ability to bind to a variety of biological targets. Benzimidazoles are known to interact with DNA, proteins, and enzymes. These interactions can lead to a variety of biological effects, including inhibition of cell growth, modulation of immune function, and anti-inflammatory activity.'

1H-benzimidazole : The 1H-tautomer of benzimidazole. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5798
CHEMBL ID306226
CHEBI ID41275
CHEBI ID36622
SCHEMBL ID5197771
SCHEMBL ID6010
SCHEMBL ID6009
MeSH IDM0097720

Synonyms (84)

Synonym
MLS001066336
smr000471839
ai3-03737
hsdb 2797
brn 0109682
einecs 200-081-4
ccris 5967
bdbm7939
1h-1,3-benzodiazole
inchi=1/c7h6n2/c1-2-4-7-6(3-1)8-5-9-7/h1-5h,(h,8,9
NCGC00091255-01
nsc-759
wln: t56 bm dnj
51-17-2
benzoimidazole
3-azaindole
bzi ,
1h-benzimidazole
benzoglyoxaline
nsc 759
n,n'-methenyl-o-phenylenediamine
azindole
1,3-diazaindene
nsc759
C02009
benziminazole
o-benzimidazole
benzimidazole ,
1,3-benzodiazole
CHEBI:41275 ,
DB02962
benzimidazole, 98%
STK397462
B0054
1h-benzoimidazole
1h-benzo[d]imidazole
CHEMBL306226
AKOS000119163
NCGC00091255-02
NCGC00257173-01
tox21_303321
dtxcid704573
dtxsid8024573 ,
cas-51-17-2
tox21_202107
NCGC00259656-01
HMS2233D03
benzimidazol
e24gx49ld8 ,
5-23-06-00196 (beilstein handbook reference)
unii-e24gx49ld8
FT-0606545
PS-5765
26985-65-9
benzimidazole [hsdb]
benzimidazole [inci]
benzimidazole [mi]
EPITOPE ID:140095
hbzim
hbim
F3366-5347
HMS3370L16
SCHEMBL5197771
AM81999
SCHEMBL6010
SCHEMBL6009
4DSU
bezimidazole
1h-benzimidazol
benz-imidazole
W-105914
CS-W019944
mfcd00005585
SY012765
Q415190
benzimidazole phase betaetha
benzimidazole phase alphalpha
benzimidazole phase gammaamma
D70829
1,3-benzodiazole, bzi
HY-Y1825
1h-1,3-benzimidazole
EN300-33475
chebi:36622

Research Excerpts

Overview

Benzimidazole is an effective structural unit in which the benzene ring is fused at the 4 and 5 positions. The core is a common moiety in a large number of natural products and pharmacologically active small molecules.

ExcerptReferenceRelevance
"The benzimidazole is an effective structural unit in which the benzene ring is fused at the 4 and 5 positions of the imidazole ring and wildly used in drug design."( Recent progress of research on anti-tumor agents using benzimidazole as the structure unit.
Cao, X; Chen, M; Li, Y; Peng, J; Peng, X; Peng, Y; Tang, G; Wu, K, 2022
)
1.45
"Benzimidazole is a nitrogen-containing fused heterocycle which has been extensively explored in medicinal chemistry. "( Recent Advancements on Benzimidazole: A Versatile Scaffold in Medicinal Chemistry.
Alam, MM; Alzhrani, ZMM; Nazreen, S, 2022
)
2.47
"Benzimidazole is an organic compound that is heterocyclic and aromatic in nature."( Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure-Activity Relationship.
Ahmed, S; Alam, MJ; Alam, O; Naim, MJ; Nawaz, F; Shrivastava, N, 2017
)
2.62
"Benzimidazole is a common kinase inhibitor scaffold and benzimidazole-based compounds interact with enzymes by multiple binding modes. "( Benzimidazole derivatives as kinase inhibitors.
Bottegoni, G; Garuti, L; Roberti, M, 2014
)
3.29
"The benzimidazole core is a common moiety in a large number of natural products and pharmacologically active small molecules. "( An efficient one-pot two catalyst system in the construction of 2-substituted benzimidazoles: synthesis of benzimidazo[1,2-c]quinazolines.
Cimarelli, C; Di Nicola, M; Diomedi, S; Giovannini, R; Hamprecht, D; Marcantoni, E; Properzi, R; Sorana, F, 2015
)
1.2

Effects

Benzimidazoles (BZ) have been the anthelmintic of choice for controlling Nematodirus battus infections since their release in the 1950s. The BZ have been intensively used in the livestock sector, particularly in small ruminants.

ExcerptReferenceRelevance
"Benzimidazoles (BZ) have been the anthelmintic of choice for controlling Nematodirus battus infections since their release in the 1950s. "( Large scale screening for benzimidazole resistance mutations in Nematodirus battus, using both pyrosequence genotyping and deep amplicon sequencing, indicates the early emergence of resistance on UK sheep farms.
Aitken, C; Avramenko, R; Bartley, DJ; Gilleard, JS; Innocent, G; Melville, LA; Mitchell, S; Morrison, AA; Rebecca Chen, PC; Redman, E; Sargison, F; Van Dijk, J, 2020
)
2.3
"Benzimidazoles have been intensively (for over 40 years) used in the livestock sector, particularly in small ruminants. "( Emergence and the spread of the F200Y benzimidazole resistance mutation in Haemonchus contortus and Haemonchus placei from buffalo and cattle.
Ali, Q; Ashraf, K; Chaudhry, U; Rashid, I; Sargison, ND; Shabbir, MZ; Shahzad, K, 2019
)
2.23
"Benzimidazole resistance has evolved in a variety of organisms and typically results from mutations in the beta-tubulin locus at specific amino acid sites. "( Sequence variation in the Trichuris trichiura beta-tubulin locus: implications for the development of benzimidazole resistance.
Anderson, TJ; Barker, GC; Bennett, AB; Bundy, DA; Michael, E, 2002
)
1.97
"The benzimidazoles (BZ), which have been used for more than 40 years, were chosen as an example."( Benzimidazole-resistant beta-tubulin alleles in a population of parasitic nematodes (Cooperia oncophora) of cattle.
Geary, TG; Johnson, SS; Pomroy, WE; Sangster, NC; Winterrowd, CA, 2003
)
2.24

Actions

ExcerptReferenceRelevance
"Benzimidazole plays an important role in the medicinal chemistry and drug discovery with many pharmacological activities which have made an indispensable anchor for discovery of novel therapeutic agents. "( Novel research strategies of benzimidazole derivatives: a review.
Barot, KP; Ghate, MD; Ivanov, I; Nikolova, S, 2013
)
2.12

Treatment

ExcerptReferenceRelevance
"Benzimidazole (BZM) treatment is given in inoperable cases but these compounds are only parasitostatic, and lifelong therapy is required."( Indications and results of liver transplantation for Echinococcus alveolar infection: an overview.
Bresson-Hadni, S; Gillet, M; Heyd, B; Koch, S; Mantion, GA; Miguet, JP; Vuitton, DA, 2003
)
1.04

Toxicity

In contrast, 2-aromatic ring substituted (benzimidazole-4,7-diones) analogues were more toxic than the highly conjugated naphthyl fused benzimidAZolequinone towards the normal cell line. 4.5% found benzimids to be safe and effective (885 patients, 2530 animals)

ExcerptReferenceRelevance
" In contrast, 2-aromatic ring substituted (benzimidazole-4,7-diones) analogues, benzimidazolequinone with a pyridine ring and mitomycin C were more toxic than the highly conjugated naphthyl fused benzimidazolequinone towards the normal cell line."( Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents.
Aldabbagh, F; Bonham, S; Carr, M; Carty, MP; Moriarty, E, 2010
)
0.86

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic descriptors of the compounds investigated were calculated in silico with the use of the established drug design software."( RP TLC data in correlation studies with in silico pharmacokinetic properties of benzimidazole and benztriazole derivatives.
Dimova, VB; Milošević, NP; Perišić-Janjić, NU, 2013
)
0.62
"This review provides an update on the following points: pharmacokinetic profile and metabolism of ilaprazole in relation to its pharmacodynamic properties; comparative data on the pharmacokinetics and pharmacodynamics of ilaprazole with currently available PPIs; and implications for studies on the therapeutic efficacy of ilaprazole in GERD."( The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
Blandizzi, C; de Bortoli, N; Giacchino, M; Marchi, S; Martinucci, I; Savarino, E; Savarino, V, 2013
)
0.39
"Different studies show that ilaprazole, a benzimidazole derivative, has an extended plasma half-life in comparison with all other approved PPIs."( The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.
Blandizzi, C; de Bortoli, N; Giacchino, M; Marchi, S; Martinucci, I; Savarino, E; Savarino, V, 2013
)
0.65

Bioavailability

ExcerptReferenceRelevance
" In our continuing efforts to identify small molecule alpha(V)beta(3) and alpha(V)beta(5) dual antagonists, we recently reported indoles 2-4 as potent and selective alpha(V)beta(3)/alpha(V)beta(5) antagonists with good oral bioavailability profile."( Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Chaikin, M; Crysler, C; Lattanze, J; Leonard, K; Manthey, CL; Marugán, JJ; Pan, W; Raboisson, P; Tomczuk, BE, 2006
)
0.33
" Compound 18c demonstrates in vivo CB1 antagonist efficacy (CB1 agonist induced hypothermia model) and is orally bioavailable in rat."( Identification and hit-to-lead optimization of a novel class of CB1 antagonists.
Baker, J; Cowley, P; Edwards, D; Ho, KK; Jokiel, P; Letourneau, JJ; McAleer, L; Ohlmeyer, MH; Olson, J; Riviello, CM; Swanson, RN; Ward, N; Webb, ML; Yang, J, 2010
)
0.36

Dosage Studied

Lambs from ewes dosed with a benzimidazole (mebendazole) developed clinical signs of haemonchosis later in the season. The combination of 2,4-difluorobenzyl benzimidsole derivative 5m and its hydrochloride 7 respectively with antibacterial Chloromycin, Norfloxacin or antifungal Fluconazole showed better antimicrobial efficiency.

ExcerptRelevanceReference
" Lambs from ewes dosed with a benzimidazole (mebendazole) before turn out, developed clinical signs of haemonchosis later in the season."( Effectiveness of clean grazing strategies in controlling Haemonchus contortus infections in sheep in the United Kingdom.
Hunt, KR; Taylor, MA; Wilson, CA, 1991
)
0.57
" During 12 weeks of twice-weekly dosing with 3000 parasite larvae (L3), eggs were observed in faeces from CRC-treated and untreated lambs given RES L3, but not CRC-treated lambs given SUS L3."( The effect of continuous drug exposure on the immune response to Trichostrongylus colubriformis in sheep.
Brown, AE; Green, R; Leathwick, DM; Miller, CM; Sutherland, IA, 1999
)
0.3
" Over the five generations, LD(50) values on dose-response were increased and worm survival occurred at higher dose rates of TBZ irrespective of the parasite stage exposed to treatment."( The effects of stage-specific selection on the development of benzimidazole resistance in Haemonchus contortus in sheep.
Goodyear, KL; Hunt, KR; Taylor, MA, 2002
)
0.56
" Ewes were dosed after lambing with the aim of controlling their periparturient rise in faecal egg output and lambs were dosed at six-week intervals throughout the summer."( Failure of moxidectin to control benzimidazole-, levamisole- and ivermectin-resistant Teladorsagia circumcinda in a sheep flock.
Bartley, DJ; Jackson, F; Moir, AC; Sargison, ND, 2005
)
0.61
" The most active compounds 5b and e gave 3/4 cures on an IP dosage of 20 mg/kg."( Dicationic near-linear biphenyl benzimidazole derivatives as DNA-targeted antiprotozoal agents.
Batista-Parra, A; Boykin, DW; Brun, R; Ismail, MA; Miao, Y; Wenzler, T; Wilson, WD, 2005
)
0.61
" Two of the compounds showed good activity in vivo in the STIB900 model for acute African trypanosomiasis; one gave 3/4 cures and the other gave 4/4 cures on ip dosage of 20 mg/kg for 4 days."( Dicationic DNA-targeted antiprotozoal agents: naphthalene replacement of benzimidazole.
Boykin, DW; Brun, R; Chackal-Catoen, S; Miao, Y; Wenzler, T; Wilson, WD, 2006
)
0.57
" In an ex vivo occupancy assay, Compound A dosed orally to rats caused a concentration dependent inhibition of the specific binding of [(125)I]-S36057 to rat caudate putamen."( Localisation of melanin-concentrating hormone receptor 1 in rat brain and evidence that sleep parameters are not altered despite high central receptor occupancy.
Able, SL; Clarke, TL; Duckworth, JM; Fish, RL; Ivarsson, M; Katugampola, SD; McCourt, C; Napier, C, 2009
)
0.35
" The most active compound, 2-[2-(5-nitro-1H-benzimidazol-1-yl)ethyl]-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one 22 revealed 95% activity at a dosage of 5 mg/kg mw after 24 h, while compounds 8 and 10 applied at the same dose showed efficacy of 90% after 48 h."( Synthesis, antitrichinnellosis and antiprotozoal activity of some novel thieno[2,3-d]pyrimidin-4(3H)-ones containing benzimidazole ring.
Anichina, K; Mavrova, ATs; Vassilev, N; Vuchev, D, 2010
)
0.57
" The combination of 2,4-difluorobenzyl benzimidazole derivative 5m and its hydrochloride 7 respectively with antibacterial Chloromycin, Norfloxacin or antifungal Fluconazole showed better antimicrobial efficiency with less dosage and broader antimicrobial spectrum than the separated use of them alone."( Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole.
Cai, GX; Damu, GL; Zhang, HZ; Zhou, CH, 2013
)
0.91
" It was found that even a very low dosage of MNBI-stabilized GNPs exhibit appreciable tumor cell mortality against cervical cancer cell lines, demonstrating the role of NO in killing cancer cells."( Nitric oxide releasing photoresponsive nanohybrids as excellent therapeutic agent for cervical cancer cell lines.
Arumugam, P; Berchmans, S; Sudhesh, P; Tamilarasan, K, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
benzimidazoleA mancude organic heterobicyclic parent that is a heterocyclic organic compound comprising fused benzene and imidazole rings.
polycyclic heteroarene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
benzimidazolyl adenosylcobamide biosynthesis from adenosylcobinamide-GDP38

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
progesterone receptorHomo sapiens (human)Potency2.42870.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency65.72080.003041.611522,387.1992AID1159552; AID1159553
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.58960.001530.607315,848.9004AID1224841
gemininHomo sapiens (human)Potency3.16230.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Membrane primary amine oxidase Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00600.50301.0000AID753428
Cytochrome P450 2B1Rattus norvegicus (Norway rat)IC50 (µMol)978.61857.40007.80008.2000AID38392; AID38394
Glutaminyl-peptide cyclotransferaseHomo sapiens (human)Ki144.00000.26202.93587.0000AID1796109; AID765872
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)200.00000.05001.43904.0000AID322753
Membrane primary amine oxidaseHomo sapiens (human)IC50 (µMol)100.00000.02001.04004.1000AID753430
Glutaminyl-peptide cyclotransferaseMus musculus (house mouse)Ki192.00006.40006.40006.4000AID1796111
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, GTPase KRas, isoform 2BHomo sapiens (human)Kd1,500.00001,500.00001,500.00001,500.0000AID977611
Chain A, GTPase KRas, isoform 2BHomo sapiens (human)Kd1,500.00001,500.00001,500.00001,500.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2B1Rattus norvegicus (Norway rat)Ks110.00001.10001.10001.1000AID184443
Cytochrome P450 1A1Rattus norvegicus (Norway rat)Ks3,200.00001.70001.70001.7000AID184441
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)Ks3,200.00001.70001.70001.7000AID184441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
MAPK cascadeGTPase KRasHomo sapiens (human)
positive regulation of protein phosphorylationGTPase KRasHomo sapiens (human)
visual learningGTPase KRasHomo sapiens (human)
gene expressionGTPase KRasHomo sapiens (human)
positive regulation of gene expressionGTPase KRasHomo sapiens (human)
glial cell proliferationGTPase KRasHomo sapiens (human)
Rac protein signal transductionGTPase KRasHomo sapiens (human)
forebrain astrocyte developmentGTPase KRasHomo sapiens (human)
actin cytoskeleton organizationGTPase KRasHomo sapiens (human)
negative regulation of epithelial cell differentiationGTPase KRasHomo sapiens (human)
regulation of synaptic transmission, GABAergicGTPase KRasHomo sapiens (human)
positive regulation of Rac protein signal transductionGTPase KRasHomo sapiens (human)
skeletal muscle cell differentiationGTPase KRasHomo sapiens (human)
negative regulation of neuron apoptotic processGTPase KRasHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityGTPase KRasHomo sapiens (human)
homeostasis of number of cells within a tissueGTPase KRasHomo sapiens (human)
striated muscle cell differentiationGTPase KRasHomo sapiens (human)
neuron apoptotic processGTPase KRasHomo sapiens (human)
positive regulation of glial cell proliferationGTPase KRasHomo sapiens (human)
epithelial tube branching involved in lung morphogenesisGTPase KRasHomo sapiens (human)
type I pneumocyte differentiationGTPase KRasHomo sapiens (human)
Ras protein signal transductionGTPase KRasHomo sapiens (human)
peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferaseGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
protein modification processGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
inflammatory responseMembrane primary amine oxidaseHomo sapiens (human)
cell adhesionMembrane primary amine oxidaseHomo sapiens (human)
amine metabolic processMembrane primary amine oxidaseHomo sapiens (human)
response to antibioticMembrane primary amine oxidaseHomo sapiens (human)
negative regulation of primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
GTPase activityGTPase KRasHomo sapiens (human)
G protein activityGTPase KRasHomo sapiens (human)
protein bindingGTPase KRasHomo sapiens (human)
protein-membrane adaptor activityGTPase KRasHomo sapiens (human)
protein-containing complex bindingGTPase KRasHomo sapiens (human)
GDP bindingGTPase KRasHomo sapiens (human)
GTP bindingGTPase KRasHomo sapiens (human)
protein bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
zinc ion bindingGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
glutaminyl-peptide cyclotransferase activityGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
copper ion bindingMembrane primary amine oxidaseHomo sapiens (human)
calcium ion bindingMembrane primary amine oxidaseHomo sapiens (human)
protein bindingMembrane primary amine oxidaseHomo sapiens (human)
primary amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
identical protein bindingMembrane primary amine oxidaseHomo sapiens (human)
protein heterodimerization activityMembrane primary amine oxidaseHomo sapiens (human)
quinone bindingMembrane primary amine oxidaseHomo sapiens (human)
aliphatic amine oxidase activityMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
Golgi membraneGTPase KRasHomo sapiens (human)
cytoplasmGTPase KRasHomo sapiens (human)
mitochondrial outer membraneGTPase KRasHomo sapiens (human)
endoplasmic reticulum membraneGTPase KRasHomo sapiens (human)
cytosolGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
focal adhesionGTPase KRasHomo sapiens (human)
cytoplasmic side of plasma membraneGTPase KRasHomo sapiens (human)
membraneGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
extracellular regionGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
specific granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
extracellular exosomeGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
tertiary granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
ficolin-1-rich granule lumenGlutaminyl-peptide cyclotransferaseHomo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
cytoplasmMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
microvillusMembrane primary amine oxidaseHomo sapiens (human)
cell surfaceMembrane primary amine oxidaseHomo sapiens (human)
membraneMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
early endosomeMembrane primary amine oxidaseHomo sapiens (human)
plasma membraneMembrane primary amine oxidaseHomo sapiens (human)
endoplasmic reticulumMembrane primary amine oxidaseHomo sapiens (human)
Golgi apparatusMembrane primary amine oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1543821Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1519676Retention time of compound at pH 7.4 by LC-UV analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID374579Apparent permeability across bovine cornea assessed as lag time of permeation by UV-visible spectrophotometer2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea.
AID658935Aqueous solubility of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1543822Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID698041Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 8 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID184441Interaction with cytochrome P450 in 3-methylcholanthrene-induced rat hepatic microsomes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID697914Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at 100 ug/ml by disk agar diffusion method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID765859Selectivity ratio of Ki for human glutaminyl cyclase H206A mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID698044Inhibition of Helicobacter pylori 26695 ATCC 700392 cytotoxin A-induced vacuolation in human AGS cells after 24 hrs by neutral red uptake assay2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID1893869Binding affinity to KRAS (unknown origin) assessed as dissociation constant2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID753430Inhibition of human VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID1231615Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID236904Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Jul-01, Volume: 15, Issue:13
Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.
AID1082988Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.1 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID1231612Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID765869Selectivity ratio of Ki for human glutaminyl cyclase I303N mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID698052Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 7 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID1422527Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum NF54 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.
AID1231626Induction of vascular disruption in HUVEC after 16 hrs by inverted microscopic analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID1231611Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate at 100 uM after 72 hrs by MTT assay relative to control2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID765864Selectivity ratio of Ki for human glutaminyl cyclase W329Y mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID765866Selectivity ratio of Ki for human glutaminyl cyclase F325N mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID765862Selectivity ratio of Ki for human glutaminyl cyclase W207F mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1148422Octanol-water partition coefficient, log P of the compound1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Synthesis and adrenergic activity of benzimidazole bioisosteres of norepinephrine and isoproterenol.
AID25099Acid dissociation constant was determined1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Synthesis of a novel class of heteroaromatic amino acids and their use in the preparation of analogues of luteinizing hormone-releasing hormone.
AID765857Selectivity ratio of Ki for human glutaminyl cyclase K144A mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID765855Selectivity ratio of Ki for human glutaminyl cyclase K144R mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID39088Inhibition of Aryl hydrocarbon hydroxylase in phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID38394Inhibitory potency to aminopyrine N-demethylase activity (P450) in hepatic microsomes from phenobarbitone-induced rats.1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID213502Anti parasitic activity against Trypanosoma cruzi2001Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19
Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine.
AID551809Displacement of Y-27632 from ROCK-1 assessed as drop in intensity of binding signals by NMR competition experiment2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
AID765870Selectivity ratio of Ki for human glutaminyl cyclase I303F mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID698045Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 5 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID765872Inhibition of human glutaminyl cyclase expressed in Escherichia coli DH5alpha using H-Gln-AMC as substrate by fluorometric analysis in presence of pyroglutamyl aminopeptidase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID698047Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 8 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID658931Antiparasitic activity against Giardia duodenalis IMSS:0989 after 48 hrs2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID1231613Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID658934Lipophilicity, logkw of the compound by RP-HPLC analysis2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID698051Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v633 at pH 5 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID753428Inhibition of rat VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment.
AID23454Partition coefficient (logP)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and in vitro LTD4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides.
AID39078Effect on Aryl hydrocarbon hydroxylase activity in 3-methylcolanthrene-induced rat liver microsomes at 1.2x10E-3M1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID284279Antiamnesic activity against Entamoeba histolytica2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
AID1231610Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate at 10 uM after 72 hrs by MTT assay relative to control2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID184443Interaction with cytochrome P450 in Phenobarbitone-induced rat hepatic microsomes1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID765867Selectivity ratio of Ki for human glutaminyl cyclase F325A mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1543818Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID765865Selectivity ratio of Ki for human glutaminyl cyclase F325Y mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID210974Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation; No reduction observed2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID658936Distribution coefficient, log D of the compound2012European journal of medicinal chemistry, Jun, Volume: 52Exploring the interplay of physicochemical properties, membrane permeability and giardicidal activity of some benzimidazole derivatives.
AID765858Selectivity ratio of Ki for human glutaminyl cyclase H206Q mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1231621Inhibition of alpha-tubulin formation in human A549 cells at 250 uM after 24 hrs by TRITC/Hoechst 33258 staining-based immunofluorescence microscopic analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID1543819Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID698053Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 8 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID374578Apparent permeability across bovine cornea by UV-visible spectrophotometer2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
Synthesis, pharmacological screening, quantum chemical and in vitro permeability studies of N-Mannich bases of benzimidazoles through bovine cornea.
AID765856Selectivity ratio of Ki for human glutaminyl cyclase K144M mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID697912Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 7 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID697913Antimicrobial activity against Helicobacter pylori 26695 ATCC 700392 at pH 5 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID26812Partition coefficient (logP)1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID1231614Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and biological evaluation of thiabendazole derivatives as anti-angiogenesis and vascular disrupting agents.
AID765861Selectivity ratio of Ki for human glutaminyl cyclase W207L mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1743052Antigiardial activity against Giardia lamblia IMSS:0989:1 incubated for 48 hrs followed by compound wash out and measured after 48 hrs2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Anti-
AID667489Inhibition of recombinant type N-terminal His6-tagged 2 R67 DHFR expressed in Escherichia coli BL21 using DHF as substrate by spectrophotometry2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.
AID765868Selectivity ratio of Ki for human glutaminyl cyclase I303V mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID698036Inhibition of NFkappaB activation expressed in human AGS cells infected with Helicobacter pylori at 20 ug/ml relative to control2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID1082989Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.2 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID67529The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID765860Selectivity ratio of Ki for human glutaminyl cyclase W207Q mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1543820Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives.
AID1519674Chromatographic hydrophobicity index of compound at 250 uM at pH 7.4 by HPLC analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: Structure-activity-toxicity, drug-likeness and efflux transport studies.
AID75268The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID698042Antimicrobial activity against metronidazole and clarithromycin-resistant Helicobacter pylori v1254 at pH 7 by microdilution method2012European journal of medicinal chemistry, Feb, Volume: 48Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
AID1422526Inhibition of beta hematin formation after 5 to 6 hrs by NP40 detergent-based assay2018European journal of medicinal chemistry, Nov-05, Volume: 159Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.
AID38392Inhibition of Aminopyrine N-demethylase in Phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID765871Selectivity ratio of Ki for human glutaminyl cyclase I303A mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID24235Partition coefficient (logP)1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.
AID39090Inhibition of Aryl hydrocarbon hydroxylase in phenobarbitone-treated rats1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazole and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats.
AID1082990Antifungal activity against Leptosphaeria maculans isolate BJ-125/UAMH-9410 assessed as mycelial growth inhibition at 0.5 mM incubated under constant light for 5 days by mycelial radial growth bioassay2012Journal of agricultural and food chemistry, Aug-15, Volume: 60, Issue:32
Metabolism and metabolites of dithiocarbamates in the plant pathogenic fungus Leptosphaeria maculans.
AID765863Selectivity ratio of Ki for human glutaminyl cyclase W329F mutant to Ki for wild type human glutaminyl cyclase2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
AID1796111QC Inhibition Testing from Article 10.1021/bi051142e: \\Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.\\2005Biochemistry, Oct-11, Volume: 44, Issue:40
Isolation, catalytic properties, and competitive inhibitors of the zinc-dependent murine glutaminyl cyclase.
AID1796109QC Inhibition Testing from Article 10.1074/jbc.M309077200: \\Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.\\2003The Journal of biological chemistry, Dec-12, Volume: 278, Issue:50
Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.
AID1802737Resonance Raman Assay from Article 10.1021/acs.biochem.7b00041: \\Interaction of Azole-Based Environmental Pollutants with the Coelomic Hemoglobin from Amphitrite ornata: A Molecular Basis for Toxicity.\\2017Biochemistry, 05-02, Volume: 56, Issue:17
Interaction of Azole-Based Environmental Pollutants with the Coelomic Hemoglobin from Amphitrite ornata: A Molecular Basis for Toxicity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012Proceedings of the National Academy of Sciences of the United States of America, Apr-03, Volume: 109, Issue:14
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,163)

TimeframeStudies, This Drug (%)All Drugs %
pre-199094 (8.08)18.7374
1990's49 (4.21)18.2507
2000's265 (22.79)29.6817
2010's629 (54.08)24.3611
2020's126 (10.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.93 (24.57)
Research Supply Index7.09 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index122.28 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (67.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (1.35%)5.53%
Reviews52 (4.38%)6.00%
Case Studies5 (0.42%)4.05%
Observational0 (0.00%)0.25%
Other1,113 (93.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Establishing a Surveillance System to Monitor the Global Patterns of Drug Efficacy and Emergence of Anthelmintic Resistance in Soil-transmitted Helminth Programs [NCT04177654]9,457 participants (Actual)Observational2019-05-15Completed
Alveolar Echinococcosis: Parasite Viability and Innovative Markers for Follow-up of Patients Treated With Albendazole - EchinoVISTA Prospective Clinical Study [NCT02876146]50 participants (Actual)Interventional2012-06-30Completed
A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI) [NCT03595553]Phase 3759 participants (Actual)Interventional2019-01-28Completed
Phase 1 Study to Evaluate the Effect of CYP Polymorphism and Gender on the Pharmacokinetics and Pharmacodynamics of Ilaprazole After Multiple Dosing [NCT01688544]Phase 127 participants (Actual)Interventional2009-01-31Completed
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon [NCT04326868]Phase 4255 participants (Actual)Interventional2019-11-11Completed
A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma [NCT03452930]Phase 192 participants (Anticipated)Interventional2018-08-13Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03595553 (8) [back to overview]Measure of β-diversity of the Gut Microbiota Between Baseline and EOT Stool Samples (Bray-Curtis Index/Dissimilarity).
NCT03595553 (8) [back to overview]Percentage of Change of α-diversity (Shannon Index) of the Microbiota in Stool Samples From Baseline to EOT.
NCT03595553 (8) [back to overview]Clinical Cure
NCT03595553 (8) [back to overview]Clinical Response
NCT03595553 (8) [back to overview]Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT).
NCT03595553 (8) [back to overview]Relative Abundance of the 3 Main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) From Baseline to EOT.
NCT03595553 (8) [back to overview]Sustained Clinical Response Over 60 Days
NCT03595553 (8) [back to overview]Sustained Clinical Response Over 90 Days

Measure of β-diversity of the Gut Microbiota Between Baseline and EOT Stool Samples (Bray-Curtis Index/Dissimilarity).

This secondary outcome measures the β-diversity of the gut microbiota in stool samples from baseline to EOT. Bray-Curtis index/dissimilarity measures how different two samples are in the microbiome composition. The Bray-Curtis dissimilarity is graded between 0 and 1, where 0 means the two samples have the same composition (that is they share all the species and every species has the same abundance), and 1 means the two samples do not share any species. (NCT03595553)
Timeframe: Day 10

InterventionBray-Curtis Index (Mean)
Ridinilazole0.7
Vancomycin0.81

[back to top]

Percentage of Change of α-diversity (Shannon Index) of the Microbiota in Stool Samples From Baseline to EOT.

This secondary outcome measures the percentage of change of α-diversity (Shannon Index) of the microbiota in stool samples from baseline to EOT. Shannon index is a weighted statistic measuring both species richness and evenness. The Shannon Index is calculated by taking the relative abundance of each species and sums the relative abundance times the natural log of the relative abundance for each species. The value is converted into a positive value by times minus one. A higher Shannon Index means higher diversity (NCT03595553)
Timeframe: Day 10

Interventionpercent change in Shannon Index (Mean)
Ridinilazole37.06
Vancomycin-7.32

[back to top]

Clinical Cure

defined as the resolution of diarrhea (<3 UBMs in the 1-day period immediately prior to EOT, that is maintained for 2 days after EOT). (NCT03595553)
Timeframe: Day 12

,
InterventionParticipants (Count of Participants)
Clinical CureClinical Cure Failure
Ridinilazole27595
Vancomycin29283

[back to top]

Clinical Response

"defined as~less than 3 unformed bowel movements (UBMs) for consecutive days and maintained through EOT without further CDI treatment at EOT + 2 days, or~the investigator's assessment that the subject no longer needs specific CDI antimicrobial treatment after completion of the course of study medication." (NCT03595553)
Timeframe: Day 12

,
InterventionParticipants (Count of Participants)
Clinical ResponseClinical Response Failure
Ridinilazole32050
Vancomycin34629

[back to top]

Number of Participants With Sustained Clinical Response (SCR) Defined as Clinical Response and no Recurrence of CDI Through 30 Days Post End of Treatment (EOT).

This primary outcome measures the number of participants with Sustained Clinical Response (SCR). SCR is defined as Clinical Response and no recurrence of CDI through 30 days post End of Treatment (EOT). At D40, D70 and D100 the Investigator or medically qualified designee will determine if the patient has a sustained clinical response or experienced RECURRENCE since the previous assessment. The Investigator will assess cure/failure and recurrence based on available information which includes, but is not limited to, improvement from baseline in the number of UBMs, signs & symptoms of CDI, and the requirement for CDI medication. The Investigator should assess cure/failure in a way that best reflects the Investigator's standard clinical practice. (NCT03595553)
Timeframe: Day 40

,
InterventionParticipants (Count of Participants)
SCR based on Clinical CureSCR based on Clinical Cure Failure
Ridinilazole238132
Vancomycin225150

[back to top]

Relative Abundance of the 3 Main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) From Baseline to EOT.

This secondary outcome measures the relative abundance of the 3 main Bile Acid Groups (Conjugated Primary, Primary and Secondary Bile Acids) from Baseline to EOT. (NCT03595553)
Timeframe: Day 10

,
Interventionpercentage of abundance (Mean)
Secondary Bile Acid Group at BaselineSecondary Bile Acid Group at EOTPrimary Bile Acid Group at BaselinePrimary Bile Acid Group at EOTConjugated Primary Bile Acid Group at BaselineConjugated Primary Bile Acid Group at EOT
Ridinilazole33.3438.1355.0355.9911.645.88
Vancomycin30.257.8757.4465.7212.3126.42

[back to top]

Sustained Clinical Response Over 60 Days

defined as Clinical Response and no recurrence of CDI through 60 days post EOT (NCT03595553)
Timeframe: Day 70

,
InterventionParticipants (Count of Participants)
Sustained Clinical Response 60 Days Post EOTSustained Clinical Response 60 Days Post EOT Failure
Ridinilazole262108
Vancomycin258117

[back to top]

Sustained Clinical Response Over 90 Days

defined as Clinical Response and no recurrence of CDI through 90 days post EOT (NCT03595553)
Timeframe: Day 100

,
InterventionParticipants (Count of Participants)
Sustained Clinical Response 90 Days Post EOTSustained Clinical Response 90 Days Post EOT Failure
Ridinilazole259111
Vancomycin249126

[back to top]